Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders re-elected George Mclean Milne Jr. and Paul Fonteyne as Class II directors through the 2029 annual meeting.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected George Mclean Milne Jr. and Paul Fonteyne as Class II directors through the 2029 annual meeting
- Paul Fonteyne received 86,275,670 votes for versus 4,770,932 withheld, indicating stronger support than Milne
- Deloitte & Touche LLP ratified as independent auditor for fiscal year 2026 with 102,036,295 votes for
- Executive compensation approved on an advisory basis, with 77,534,824 votes for versus 13,490,653 against
- Director and compensation votes passed, but compensation opposition remains material at approximately 17% of votes cast excluding broker non-votes
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.